LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
about
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancerSuppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53‑deficient pancreatic cancer cells.
P2860
LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
LY2603618, a selective CHK1 in ...... ine in xenograft tumor models.
@en
LY2603618, a selective CHK1 in ...... ine in xenograft tumor models.
@nl
type
label
LY2603618, a selective CHK1 in ...... ine in xenograft tumor models.
@en
LY2603618, a selective CHK1 in ...... ine in xenograft tumor models.
@nl
prefLabel
LY2603618, a selective CHK1 in ...... ine in xenograft tumor models.
@en
LY2603618, a selective CHK1 in ...... ine in xenograft tumor models.
@nl
P2093
P2860
P1476
LY2603618, a selective CHK1 in ...... ine in xenograft tumor models.
@en
P2093
Bonita Jones
Constance King
Darlene Barnard
David Barda
Gregory Donoho
H Bruce Diaz
Mark Marshall
Richard Beckmann
Teresa Burke
P2860
P2888
P356
10.1007/S10637-015-0310-Y
P577
2015-11-27T00:00:00Z
P5875
P6179
1008467536